Rezolute (RZLT) Competitors $4.39 +0.16 (+3.78%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RZLT vs. AVDL, COLL, SEPN, ZYME, BCAX, GYRE, PSTX, PAHC, COGT, and NUVBShould you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), Septerna (SEPN), Zymeworks (ZYME), Bicara Therapeutics (BCAX), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Phibro Animal Health (PAHC), Cogent Biosciences (COGT), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Rezolute vs. Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Zymeworks Bicara Therapeutics Gyre Therapeutics Poseida Therapeutics Phibro Animal Health Cogent Biosciences Nuvation Bio Rezolute (NASDAQ:RZLT) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment. Which has preferable earnings and valuation, RZLT or AVDL? Rezolute has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.27-3.46Avadel Pharmaceuticals$138.16M7.19-$160.28M-$0.79-13.05 Which has more volatility & risk, RZLT or AVDL? Rezolute has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Do insiders and institutionals believe in RZLT or AVDL? 83.0% of Rezolute shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 18.4% of Rezolute shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is RZLT or AVDL more profitable? Rezolute has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Rezolute's return on equity of -69.83% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -69.83% -62.16% Avadel Pharmaceuticals -52.53%-93.34%-44.77% Do analysts rate RZLT or AVDL? Rezolute presently has a consensus price target of $24.13, suggesting a potential upside of 449.54%. Avadel Pharmaceuticals has a consensus price target of $24.43, suggesting a potential upside of 136.94%. Given Rezolute's higher possible upside, equities analysts clearly believe Rezolute is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RZLT or AVDL? In the previous week, Avadel Pharmaceuticals had 4 more articles in the media than Rezolute. MarketBeat recorded 8 mentions for Avadel Pharmaceuticals and 4 mentions for Rezolute. Rezolute's average media sentiment score of 1.60 beat Avadel Pharmaceuticals' score of 1.20 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avadel Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer RZLT or AVDL? Avadel Pharmaceuticals received 275 more outperform votes than Rezolute when rated by MarketBeat users. However, 78.82% of users gave Rezolute an outperform vote while only 66.02% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRezoluteOutperform Votes6778.82% Underperform Votes1821.18% Avadel PharmaceuticalsOutperform Votes34266.02% Underperform Votes17633.98% SummaryRezolute beats Avadel Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RZLT vs. The Competition Export to ExcelMetricRezolutePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.10M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-3.4610.5991.3417.19Price / SalesN/A195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book2.005.104.794.78Net Income-$68.46M$151.51M$120.07M$225.60M7 Day Performance-4.36%-2.15%-1.90%-1.23%1 Month Performance-9.67%-3.14%11.45%3.37%1 Year Performance388.16%11.50%30.63%16.58% Rezolute Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RZLTRezolute3.1803 of 5 stars$4.39+3.8%$24.13+449.5%+387.8%$245.10MN/A-3.4640Positive NewsAVDLAvadel Pharmaceuticals2.6583 of 5 stars$10.94+5.3%$24.43+123.3%-24.0%$1.05B$138.16M-13.15154Positive NewsCOLLCollegium Pharmaceutical3.8414 of 5 stars$30.68+2.0%$42.60+38.9%-0.4%$989.43M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2189 of 5 stars$21.83-2.5%$43.67+100.0%N/A$969.25MN/A0.00N/AZYMEZymeworks2.8055 of 5 stars$13.83+9.9%$18.83+36.2%+52.5%$952.61M$76.01M-9.25290Analyst ForecastNews CoverageGap DownBCAXBicara TherapeuticsN/A$17.50flat$43.00+145.7%N/A$952.28MN/A0.0032News CoverageGap DownGYREGyre Therapeutics0.6053 of 5 stars$10.14+5.2%N/A-61.2%$948.30M$105.03M0.0040News CoverageGap UpPSTXPoseida Therapeutics3.7522 of 5 stars$9.52+0.1%$9.50-0.2%+193.5%$930.77M$64.70M-15.10260Positive NewsPAHCPhibro Animal Health4.1314 of 5 stars$22.74+0.3%$19.00-16.4%+89.6%$921.04M$1.05B52.561,940Analyst ForecastCOGTCogent Biosciences1.9533 of 5 stars$8.28+1.6%$14.83+79.1%+51.9%$914.61MN/A-3.2980NUVBNuvation Bio2.3876 of 5 stars$2.68+2.7%$6.60+146.3%+90.1%$902.01MN/A0.0060News Coverage Related Companies and Tools Related Companies AVDL Alternatives COLL Alternatives SEPN Alternatives ZYME Alternatives BCAX Alternatives GYRE Alternatives PSTX Alternatives PAHC Alternatives COGT Alternatives NUVB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RZLT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RZLT Stock Alerts